Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology - iCrowdNewswire
  • Spain
  • Brazil
  • Russia
  • France
  • Germany
  • China
  • Korea
  • Japan

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Mar 14, 2018 2:50 PM ET

Technical Perspectives on Biotech Stocks — Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology

Disclosure NewswireTM

iCrowdNewswire - Mar 14, 2018

NEW YORK,  — strives to bring the best free research to the investment community.  Today we are offering reports on VCEL, VKTX, VTGN, and ZIOP which can be accessed for free by signing up to Research reports have been issued by on Vericel Corp. (NASDAQ: VCEL), Viking Therapeutics Inc. (NASDAQ: VKTX), VistaGen Therapeutics Inc. (NASDAQ: VTGN), and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Biotechnology companies use live organisms or their products, such as bacteria or enzymes, to manufacture their medicines. Their drugs have a biological basis, while those of pharmaceutical companies have a chemical basis. All you have to do is sign up today for this free limited time offer by clicking the link below.



Shares in Massachusetts headquartered Vericel Corp. rose 1.34%, ending Tuesday’s trading session at $11.35. The stock recorded a trading volume of 940,359 shares. The Company’s shares have surged 71.97% in the last month, 140.21% over the last three months, and 298.25% over the past year. The stock is trading 51.10% and 133.39% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, have a Relative Strength Index (RSI) of 70.87.  

On March 06th, 2018, research firm Needham reiterated its ‘Buy’ rating on the Company’s stock with an increase of the target price from $5 a share to $15 a share.

On March 12th, 2018, Vericel announced that it will host an Analyst and Investor Day on April 11th, 2018, from 8:30 a.m. to 11:00 a.m. ET in New York City. The Company’s executives will provide business updates and facilitate discussions with surgeon thought leaders, who currently use Vericel’s products in their practices. Also speaking will be Dara Torres, world champion swimmer, best-selling author, five-time Olympian, and MACI® (autologous cultured chondrocytes on porcine collagen membrane) patient. Get the full research report on VCEL for free by clicking below at:

Viking Therapeutics

California headquartered Viking Therapeutics Inc.’s stock dropped 4.79%, closing the day at $5.76 with a total trading volume of 758,237 shares. The Company’s shares have advanced 41.18% in the previous three months and 336.36% over the past year. The stock is trading 2.58% and 106.76% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Viking Therapeutics, which focuses on the development of therapies for metabolic and endocrine disorders, have an RSI of 45.36. 

On March 06th, 2018, Viking Therapeutics announced that its CEO, Brian Lian, Ph.D., will deliver a corporate presentation at H.C. Wainwright & Co.’s 2nd Annual NASH Investor Conference on March 19th, 2018, at 10:40 p.m. ET at St. Regis Hotel in New York. Mr. Lian will also deliver a corporate presentation at Oppenheimer’s 28th Annual Healthcare Conference on March 20th, 2018, at 2:10 p.m. ET at Westin New York Grand Central Hotel in New York. Access the free research report on VKTX now by signing up at:

VistaGen Therapeutics

On Tuesday, shares in California headquartered VistaGen Therapeutics Inc. recorded a trading volume of 581,643 shares. The stock ended the day 4.42% higher at $1.30. The Company’s shares have advanced 12.07% in the past month. The stock is trading above its 50-day moving average by 3.52%. Furthermore, shares of VistaGen Therapeutics, which engages in developing and commercializing product candidates for patients with central nervous system diseases, have an RSI of 52.37.  

On March 05th, 2018, VistaGen Therapeutics announced that Shawn Singh, CEO, will present at Oppenheimer’s 28thAnnual Healthcare Conference on March 21st, 2018, at 8:00 a.m. ET in New York City. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VTGN at:


Massachusetts headquartered ZIOPHARM Oncology Inc.’s stock climbed 1.14%, finishing yesterday’s session at $4.44 with a total trading volume of 1.36 million shares. The Company’s shares have advanced 14.14% in the last month and 0.23% in the previous three months. The stock is trading above its 50-day moving average by 7.45%. Additionally, shares of ZIOPHARM Oncology have an RSI of 59.33.  

On March 01st, 2018, ZIOPHARM Oncology announced its results for the quarter and year ended December 31st, 2017. For Q4 2017, net loss applicable to the common stockholders was $18.3 million; R&D expenses were $11.2 million; and G&A expenses were $3.9 million. For the full year 2017, net loss applicable to the common stockholders was $73.3 million; R&D expenses were $45.1 million; and G&A expenses were $14.8 million. Aspiring Member, please take a moment to register below for your free research report on ZIOP at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

Contact Information:

Email: [email protected]
Phone number:+21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

View Related News >